Globus Medical, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Globus Medical develops and sells musculoskeletal medical devices and enabling technologies, including implants, neuromonitoring services, imaging, navigation, and robotic systems. The September 2023 NuVasive merger materially expanded the business; Q1 2023 results do not include NuVasive and are therefore not directly comparable.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net sales | $606.7 million | $276.7 million |
| Gross profit / gross margin | $365.2 million / 60.2% | $205.9 million / 74.4% |
| Operating income / margin | $8.0 million / 1.3% | $56.4 million / 20.4% |
| Net income (loss) | $(7.1) million | $49.1 million |
| Diluted earnings (loss) per share | $(0.05) | $0.48 |
| Operating cash flow | $52.4 million | $53.3 million |
- Revenue by category: Musculoskeletal Solutions was $574.7 million; Enabling Technologies was $32.0 million. U.S. sales were $482.9 million and international sales $123.7 million, or 20.4% of total sales.
- Reported sales rose 119.3% year over year, primarily reflecting the addition of NuVasive, alongside growth in spine products and enabling technologies. U.S. sales increased 106.3% and international sales 190.7%.
- Gross margin declined substantially. Cost of sales included $53.7 million of amortization of NuVasive inventory fair-value step-up; $77.4 million of that step-up remained at quarter-end.
- Operating expenses included $19.1 million of restructuring costs. Research and development was $57.3 million, including $12.6 million of acquired in-process R&D charged to expense. Selling, general and administrative expense was $248.7 million.
- Other expense, net was $16.6 million, including $15.4 million of foreign-currency transaction losses and net interest expense of $1.9 million. The income tax benefit was $1.4 million; the reported effective tax rate was 16.8%.
Balance sheet, liquidity, and cash flow
- At March 31, cash and cash equivalents were $354.1 million and marketable securities totaled $131.7 million. Combined cash and securities were $485.7 million, compared with $593.2 million at December 31, 2023.
- Total assets were $4.94 billion; total liabilities were $1.02 billion. Inventory was $816.2 million and accounts receivable $534.3 million.
- The company had $450.0 million principal amount of 0.375% convertible notes due March 15, 2025, with a $424.0 million balance-sheet carrying amount. The notes become generally convertible beginning September 15, 2024, subject to their terms.
- A $400 million revolving credit facility, maturing in September 2028, was undrawn at quarter-end; the company reported compliance with its covenants.
- Investing cash outflow was $46.6 million, including $28.6 million of property and equipment purchases and $12.6 million for acquisitions and acquired assets. Financing cash outflow was $115.7 million, including $83.3 million of share repurchases and acquisition-related payments.
- Cash and cash equivalents fell by $113.2 million during the quarter to $354.1 million. The company said cash, securities, and operating cash flows should meet foreseeable liquidity needs, while noting possible future funding needs.
Material changes, outlook, and risks
- The NuVasive merger drives much of the year-over-year revenue and expense increase and adds acquired intangible assets, contingent consideration, and integration demands. Management cited integration and realization of anticipated synergies as risks.
- The 2024 Synergy Plan is intended to optimize the organization and combine commercial operations. Q1 restructuring and related costs totaled $24.0 million across expense classifications; $10.6 million remained accrued at March 31.
- No specific financial guidance or quantified outlook is provided in this filing. Management describes opportunities to expand U.S. and international sales, develop products, and grow adoption of enabling technologies, while noting that adoption markets remain early-stage.
- Key risks cited include merger integration and synergy execution, product demand and competition, attracting and retaining sales personnel, product development, regulatory and legal matters, and general economic conditions. Management reported no material changes to the risk factors in its 2023 Form 10-K.
- The company reported a defense jury verdict in the Moskowitz patent litigation in December 2023 and had recorded no related liability other than counsel fees. It cautions that other proceedings could still adversely affect earnings, financial position, or cash flows.
- During Q1, Globus repurchased 1.6 million shares for $83.3 million at an average $52.18 per share; $191.7 million remained authorized.
Important facts for investors to verify
- How much of reported sales growth reflects acquired NuVasive revenue versus organic growth, and whether comparable-period or pro forma growth measures are available.
- How margins evolve as purchase-accounting inventory step-up amortization declines and merger integration and restructuring costs progress.
- The plan to address the $450 million notes due in March 2025, including potential cash repayment, refinancing, or conversion effects.
- Cash generation, working-capital trends, acquisition-related payments, and the pace of share repurchases relative to liquidity needs.
- Progress on integration, synergy realization, and adoption of enabling technologies, as well as any developments in contingent obligations or legal proceedings.